Mitochondrial iron accumulation exacerbates hepatic toxicity caused by hepatitis C virus core protein

Toxicology and Applied Pharmacology

Volumn 282, Issue 3, 2015, Pages 237-243

  Sekine, Shuichi ^a   Ito, Konomi ^a   Watanabe, Haruna ^a   Nakano, Takafumi ^a   Moriya, Kyoji ^b   Shintani, Yoshizumi ^b   Fujie, Hajime ^b   Tsutsumi, Takeya ^b   Miyoshi, Hideyuki ^b   Fujinaga, Hidetake ^b   Shinzawa, Seiko ^b   Koike, Kazuhiko ^b   Horie, Toshiharu ^a  

^a CHIBA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Ca2+ uniporter; Fenton reaction; Hepatitis C virus; Reactive oxygen species; Ru360

Indexed keywords

CORE PROTEIN; HEPATITIS C VIRUS CORE PROTEIN; NITRILOTRIACETATE IRON; PROTEIN INHIBITOR; REACTIVE OXYGEN METABOLITE; RU360 PROTEIN; UNCLASSIFIED DRUG; FERRIC ION; IRON; NITRILOTRIACETIC ACID; NUCLEOCAPSID PROTEIN, HEPATITIS C VIRUS;

ANIMAL EXPERIMENT; ARTICLE; CYTOTOXICITY; DISEASE EXACERBATION; FATTY LIVER; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IRON OVERLOAD; IRON TRANSPORT; LIVER CELL CARCINOMA; LIVER MITOCHONDRION; LIVER TOXICITY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TRANSGENIC MOUSE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL SURVIVAL; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; METABOLISM; TUMOR CELL LINE;

HEPATITIS C VIRUS; MUS MUSCULUS;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; FERRIC COMPOUNDS; HEP G2 CELLS; HUMANS; IRON; IRON OVERLOAD; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOCHONDRIA, LIVER; NITRILOTRIACETIC ACID; REACTIVE OXYGEN SPECIES; VIRAL CORE PROTEINS;

EID: 84920901927     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.12.004     Document Type: Article

References (33)

1. Awai M., Narasaki M., Yamanoi Y., Seno S. Induction of diabetes in animals by parenteral administration of ferric nitrilotriacetate. A model of experimental hemochromatosis. Am. J. Pathol. 1979, 95:663-673.
2. Bartenschlager R., Lohmann V. Replication of hepatitis C virus. J. Gen. Virol. 2000, 81:1631-1648.
3. Bernardi P. Mitochondrial transport of cations: channels, exchangers, and permeability transition. Physiol. Rev. 1999, 79:1127-1155.
4. Bonkovsky H.L., Banner B.F., Rothman A.L. Iron and chronic viral hepatitis. Hepatology 1997, 25:759-768.
5. Bukh J., Miller R.H., Purcell R.H. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin. Liver Dis. 1995, 15:41-63.
6. Choi J., Ou J.H. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G847-G851.
7. Farinati F., Cardin R., De Maria N., Della Libera G., Marafin C., Lecis E., et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J. Hepatol. 1995, 22:449-456.
8. Hayashi H., Takikawa T., Nishimura N., Yano M., Isomura T., Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am. J. Gastroenterol. 1994, 89:986-988.
9. Ikeda K., Saitoh S., Suzuki Y., Kobayashi M., Tsubota A., Koida I., et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J. Hepatol. 1998, 28:930-938.
10. Kageyama F., Kobayashi Y., Murohisa G., Shimizu E., Suzuki F., Kikuyama M., et al. Failure to respond to interferon-alpha 2a therapy is associated with increased hepatic iron levels in patients with chronic hepatitis C. Biol. Trace Elem. Res. 1998, 64:185-196.
11. Kato J., Kobune M., Nakamura T., Kuroiwa G., Takada K., Takimoto R., et al. Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res. 2001, 61:8697-8702.
12. Kato J., Miyanishi K., Kobune M., Nakamura T., Takada K., Takimoto R., et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J. Gastroenterol. 2007, 42:830-836.
13. Korenaga M., Wang T., Li Y., Showalter L.A., Chan T., Sun J., et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J. Biol. Chem. 2005, 280:37481-37488.
14. Kowdley K.V. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004, 127:S79-S86.
15. Lau J.Y., Xie X., Lai M.M., Wu P.C. Apoptosis and viral hepatitis. Semin. Liver Dis. 1998, 18:169-176.
16. 2+ uniporter activity. FASEB J. 2007, 21:2474-2485.
17. Maeda T., Miyazono Y., Ito K., Hamada K., Sekine S., Horie T. Oxidative stress and enhanced paracellular permeability in the small intestine of methotrexate-treated rats. Cancer Chemother. Pharmacol. 2010, 65:1117-1123.
18. Masubuchi Y., Nakayama S., Horie T. Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 2002, 35:544-551.
19. Moriya K., Nakagawa K., Santa T., Shintani Y., Fujie H., Miyoshi H., et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res. 2001, 61:4365-4370.
20. Moriya K., Miyoshi H., Shinzawa S., Tsutsumi T., Fujie H., Goto K., et al. Hepatitis C virus core protein compromises iron-induced activation of antioxidants in mice and HepG2 cells. J. Med. Virol. 2010, 82:776-792.
21. Muckenthaler M.U. Fine tuning of hepcidin expression by positive and negative regulators. Cell Metab. 2008, 8:1-3.
22. Nishioka K., Watanabe J., Furuta S., Tanaka E., Iino S., Suzuki H., et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991, 67:429-433.
23. Oberley T.D. Oxidative damage and cancer. Am. J. Pathol. 2002, 160:403-408.
24. Okuda M., Li K., Beard M.R., Showalter L.A., Scholle F., Lemon S.M., et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002, 122:366-375.
25. Olynyk J.K., Reddy K.R., Di Bisceglie A.M., Jeffers L.J., Parker T.I., Radick J.L., et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995, 108:1104-1109.
26. Otani K., Korenaga M., Beard M.R., Li K., Qian T., Showalter L.A., et al. Hepatitis C virus core protein, cytochrome P450 2E1, and alcohol produce combined mitochondrial injury and cytotoxicity in hepatoma cells. Gastroenterology 2005, 128:96-107.
27. Park J.S., Yang J.M., Min M.K. Hepatitis C virus nonstructural protein NS4B transforms NIH3T3 cells in cooperation with the Ha-ras oncogene. Biochem. Biophys. Res. Commun. 2000, 267:581-587.
28. 2+ uniporter. Cell Calcium 2012, 52:16-21.
29. Ray R.B., Meyer K., Ray R. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology 2000, 271:197-204.
30. Silva I.S., Perez R.M., Oliveira P.V., Cantagalo M.I., Dantas E., Sisti C., et al. Iron overload in patients with chronic hepatitis C virus infection: clinical and histological study. J. Gastroenterol. Hepatol. 2005, 20:243-248.
31. Walters G.O., Miller F.M., Worwood M. Serum ferritin concentration and iron stores in normal subjects. J. Clin. Pathol. 1973, 26:770-772.
32. Wang T., Weinman S.A. Causes and consequences of mitochondrial reactive oxygen species generation in hepatitis C. J. Gastroenterol. Hepatol. 2006, 21(Suppl. 3):S34-S37.
33. Wang T., Campbell R.V., Yi M.K., Lemon S.M., Weinman S.A. Role of hepatitis C virus core protein in viral-induced mitochondrial dysfunction. J. Viral Hepat. 2010, 17:784-793.